Cardiovascular safety and diabetes drug development (Q83400035)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Cardiovascular safety and diabetes drug development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Daniel J Drucker

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

language of work or name

English

0 references

publication date

1 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

377

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

9770

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

977-979

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json

Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4

7 January 2021

Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4

7 January 2021

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4

7 January 2021

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4

7 January 2021

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4

7 January 2021

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4

7 January 2021

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4

7 January 2021

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4

7 January 2021

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4

7 January 2021

Assessing the cardiovascular safety of diabetes therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4

7 January 2021

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4

7 January 2021

10.1016/S0140-6736(10)62299-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json